Targeted therapy has always been the focus in developing therapeutic approaches in cancer, especially in the treatment of acute myeloid leukemia (AML). A new small molecular inhibitor, JQ1, targeting BRD4, which recognizes the acetylated lysine residues, has been shown to induce cell cycle arrest in different cancers by inhibiting MYC oncogene. | BET Bromodomain inhibition promotes Derepression of TXNIP and activation of ASK1- MAPK pathway in acute myeloid leukemia